willow glp 1 Willow Health

Retatrutide activates GIPR and GCGR , achieving over 20% weight loss in phase 2 trials

GLP-1RAs pose risks of severe eye complications, particularly worsening diabetic retinopathy with rapid and significant HbA1c reduction

Decisions about GLP-1 medications can add another layer and deserve clear information, honest discussion, and individualized support

Diabetologia 45 , 623634 (2002)

Conversely and surprisingly, an anabolizing agent like GLP-1RAs can also upregulate this kinase through cAMP (Cyclic adenosine monophosphate) accumulation

For some context, the most potent injectable drugs in development today have helped people achieve up to 28% weight loss